{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:00:44Z","timestamp":1788199244084,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T00:00:00Z","timestamp":1709510400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019265","name":"Yuhan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.lungcan.2024.107509","type":"journal-article","created":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T21:40:56Z","timestamp":1708378856000},"page":"107509","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201"],"prefix":"10.1016","volume":"190","author":[{"given":"Byoung","family":"Chul Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Youn","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki","family":"Hyeong Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Gyoo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Wan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young","family":"Joo Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-We","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun","family":"Kyung Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0408-8997","authenticated-orcid":false,"given":"Joo-Hang","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyeong-Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung","family":"Sook Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NaMi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jang","family":"Young Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7511-864X","authenticated-orcid":false,"given":"Hyejoo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5376-5109","authenticated-orcid":false,"given":"Myung-Ju","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.lungcan.2024.107509_b0005","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/s12885-022-09421-7","article-title":"Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer-is there a \u201ctail plateau\u201d in the survival curve of these patients?","volume":"22","author":"Shimamura","year":"2022","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2024.107509_b0010","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jtho.2015.12.103","article-title":"Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs","volume":"11","author":"Lin","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2024.107509_b0015","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)","volume":"9","author":"Shi","year":"2014","journal-title":"J. Thorac. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2024.107509_b0020","article-title":"Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function","volume":"14","author":"Kitadai","year":"2022","journal-title":"Analysis"},{"issue":"suppl_1","key":"10.1016\/j.lungcan.2024.107509_b0025","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1093\/annonc\/mdx702","article-title":"Overview of current systemic management of EGFR-mutant NSCLC","volume":"29","author":"Hsu","year":"2018","journal-title":"Ann. Oncol."},{"issue":"Suppl 1","key":"10.1016\/j.lungcan.2024.107509_b0030","first-page":"S23","article-title":"EGFR first- and second-generation TKIs-there is still place for them in EGFR-mutant NSCLC patients","volume":"8","author":"Lee","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2024.107509_b0035","first-page":"147","article-title":"EGFR T790M: revealing the secrets of a gatekeeper","volume":"8","author":"Ko","year":"2017","journal-title":"Lung Cancer (auckl)"},{"issue":"4","key":"10.1016\/j.lungcan.2024.107509_b0040","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"E.G.C.E.a. clinicalguidelines@esmo.org, Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2024.107509_b0045","unstructured":"National Comprehensive Cancer Network, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) - Non\u2013Small Cell Lung Cancer Version 1.2024, 2024. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1450. (Accessed 15-Jan-2024."},{"issue":"28","key":"10.1016\/j.lungcan.2024.107509_b0050","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1200\/JCO.22.00824","article-title":"Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline","volume":"40","author":"Singh","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2024.107509_b0055","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3389\/fonc.2018.00208","article-title":"Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer","volume":"8","author":"Kelly","year":"2018","journal-title":"Front. Oncol."},{"issue":"Suppl 3","key":"10.1016\/j.lungcan.2024.107509_b0060","doi-asserted-by":"crossref","first-page":"S247","DOI":"10.21037\/tlcr.2019.06.01","article-title":"Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer","volume":"8","author":"Andrews Wright","year":"2019","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"10.1016\/j.lungcan.2024.107509_b0065","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.lungcan.2015.01.020","article-title":"Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers","volume":"88","author":"Rangachari","year":"2015","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2024.107509_b0070","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jtho.2021.11.025","article-title":"A Phase 1\/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors","volume":"17","author":"Cho","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2024.107509_b0075","first-page":"2575","article-title":"YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell","volume":"25","author":"Yun","year":"2019","journal-title":"Lung Cancer"},{"issue":"26","key":"10.1016\/j.lungcan.2024.107509_b0080","first-page":"4208","article-title":"Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301","volume":"41","author":"Cho","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2024.107509_b0085","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2217\/fon-2021-0923","article-title":"MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer","volume":"18","author":"Cho","year":"2022","journal-title":"Future Oncol."},{"key":"10.1016\/j.lungcan.2024.107509_b0090","unstructured":"Ministry of Food and Drug Safety Republic of Korea. LECLAZA (lazertinib): Republic of Korea prescribing information. 2021., 2021. https:\/\/nedrug.mfds.go.kr\/pbp\/CCBBB01\/getItemDetailCache?cacheSeq=202100467aupdateTs2023-07-04%2015:10:26.441634b. (Accessed 2 October 2023."},{"issue":"20","key":"10.1016\/j.lungcan.2024.107509_b0095","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1158\/1078-0432.CCR-16-0399","article-title":"Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity","volume":"22","author":"Ballard","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.lungcan.2024.107509_b0100","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.jtho.2022.01.007","article-title":"The Challenges of Third-Generation EGFR Tyrosine Kinase Inhibitors in the Therapy of Advanced NSCLC","volume":"17","author":"Wang","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2024.107509_b0105","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/S1470-2045(19)30504-2","article-title":"Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1\u20132 study","volume":"20","author":"Ahn","year":"2019","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2024.107509_b0110","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2024.107509_b0115","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2024.107509_b0120","doi-asserted-by":"crossref","unstructured":"K. Azuma, M. Nishio, H. Hayashi, K. Kiura, M. Satouchi, S. Sugawara, T. Hida, ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor-na\u00efve Japanese patients with EGFR mutation-positive non-small-cell lung cancer, 109(8) (2018) 2532-2538.","DOI":"10.1111\/cas.13651"},{"issue":"21","key":"10.1016\/j.lungcan.2024.107509_b0125","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2024.107509_b0130","article-title":"EGFR tyrosine kinase inhibitor lazertinib activates a subset of mouse sensory neurons via TRPA1","author":"Kim","year":"2023","journal-title":"J. Pain"},{"issue":"8","key":"10.1016\/j.lungcan.2024.107509_b0135","first-page":"4223","article-title":"Chemotherapy-induced peripheral neuropathy (CIPN): current therapies and topical treatment option with high-concentration capsaicin","volume":"29","author":"Maih\u00f6fner","year":"2021","journal-title":"Support Care Cancer"},{"issue":"10","key":"10.1016\/j.lungcan.2024.107509_b0140","article-title":"Cardiac safety assessment of lazertinib: findings from patients with EGFR Mutation-positive advanced NSCLC and preclinical studies","volume":"2","author":"Jang","year":"2021","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2024.107509_b0145","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.jtho.2023.06.016","article-title":"Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Na\u00edve Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301","volume":"18","author":"Reungwetwattana","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2024.107509_b0150","first-page":"99","article-title":"Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset","volume":"14","author":"Cho","year":"2019","journal-title":"JTO Clin. Res. Rep."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500224000424?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500224000424?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:07:00Z","timestamp":1759237620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500224000424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":30,"alternative-id":["S0169500224000424"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.107509","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.107509","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107509"}}